Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. [2] Symptoms of cholangiocarcinoma may include abdominal pain , yellowish skin , weight loss , generalized itching , and fever. [ 1 ]
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). [ 1 ] [ 3 ] It is a kinase inhibitor. [ 1 ] [ 6 ] It is taken by mouth .
Infigratinib is currently in clinical trials for the treatment of children with achondroplasia.Infigratinib is now in a Phase 3 clinical trial. [12]Infigratinib was originally developed at a higher dose for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion ...
Silmitasertib is in clinical trials for use as an adjunct to chemotherapy in the treatment of cholangiocarcinoma (bile duct cancer), [1] is in phase I and II clinical trials for the treatment of recurrent Sonic Hedgehog (SHH) medulloblastoma, [2] [3] and in preclinical development for other cancers, including hematological and lymphoid ...
Durvalumab [1] AstraZeneca UK: unresectable Stage III non-small cell lung cancer: Ibalizumab-uiyk [1] Theratechnologies: human immunodeficiency virus type 1 (HIV-1) infection Brentuximab vedotin [1] Seattle Genetics: Hodgkin lymphoma: Ipilimumab [1] Bristol-Myers Squibb: renal cell carcinoma: Nivolumab [1] Bristol-Myers Squibb: renal cell ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Primary sclerosing cholangitis is one of the major known risk factors for cholangiocarcinoma, [40] a cancer of the biliary tree, for which the lifetime risk among patients with PSC is 10-15%. [3] This represents a 400-fold greater risk of developing cholangiocarcinoma compared to the general population. [ 1 ]